胃癌组织中Versican与WTAP的表达及其对术后复发或转移的影响研究

Expressions of Versican and WTAP in gastric cancer tissues and their roles in postoperative recurrence or metastasis

摘要:

目的 探讨胃癌组织中Versican与成肾细胞瘤1-结合蛋白（WTAP）的表达及其对术后复发或转移的影响。方法 选取2016年4月—2018年11月淮安市第一人民医院分院收治101例胃癌患者。患者均行手术切除，术后随访3年。采用免疫组织化学法检测癌组织、癌旁组织中Versican和WTAP的表达，分析癌组织中Versican和WTAP表达情况与临床病理特征的关系，分析影响胃癌患者术后复发转移的因素，Kapaln-Meier法绘制生存曲线，比较Versican和WTAP阳性表达与阴性表达患者的无病生存率。结果 癌组织Versican与WTAP阳性表达率高于癌旁组织（P <0.05）。低分化、肿瘤分期为Ⅲ期、突破浆膜、淋巴结转移的胃癌患者癌组织Versican、WTAP阳性表达率分别高于中、高分化，Ⅰ或Ⅱ期，未突破浆膜，无淋巴结转移患者（P <0.05）。单因素分析显示：病理分级、肿瘤分期、浸润深度、淋巴结转移、Versican阳性、WTAP阳性是影响胃癌患者术后复发转移的影响因素（P <0.05）。多因素Cox回归分析结果显示：病理分级［R^R=4.943（95% CI：2.034，12.013）］、肿瘤分期［R^R=5.058（95% CI：2.081，12.293）］、淋巴结转移［R^R=3.991（95 CI：1.642，9.699）］、Versican阳性表达［R^R=4.263（95% CI：1.754，10.361）］和WTAP阳性表达［R^R=5.038（95% CI：2.073，12.244）］是影响胃癌患者术后复发转移的独立因素（P <0.05）。Versican、WTAP阳性表达患者与阴性表达患者的无病生存率比较，差异有统计学意义（P <0.05）。结论 胃癌患者癌组织中Versican及WTAP蛋白表达与临床病理特征及预后有关，Versican、WTAP阳性表达患者术后复发转移风险高。

Abstract:

Objective To explore the expressions of Versican and Wilms' tumor 1-associating protein (WTAP) in gastric cancer tissue and their roles in postoperative recurrence or metastasis.Methods A total of 101 patients with gastric cancer admitted to our hospital from April 2016 to November 2018 were selected. All patients underwent surgical resections and were followed up for 3 years. Immunohistochemistry was used to detect the expressions of Versican and WTAP in the cancer tissues and adjacent tissues, which were compared between the two groups. The relationship between the expressions of Versican and WTAP in gastric cancer tissues and the clinicopathological characteristics, the factors affecting the postoperative recurrence and metastasis of gastric cancer patients, and the relationship between the expressions of Versican and WTAP in cancer tissues and the disease-free survival of patients with gastric cancer were analyzed.Results The positive expression rates of Versican and WTAP in cancer tissues were higher than those in adjacent tissues (P < 0.05). The positive expression rates of Versican and WTAP in the cancer tissues of patients with poorly differentiated gastric cancer, stage Ⅲ gastric cancer, serosal invasion of gastric cancer, and lymph node metastasis were higher than those of patients with moderately and well differentiated gastric cancer, stage Ⅰ and Ⅱ gastric cancer, no serosal invasion of gastric cancer, and no lymph node metastasis (P < 0.05). The univariable analysis revealed that the pathological grade, tumor stage, depth of tumor invasion, lymph node metastasis, Versican positivity and WTAP positivity were factors affecting the postoperative recurrence or metastasis in gastric cancer patients. The Cox regression analysis showed that pathological grade [R^R = 4.943 (95% CI: 2.034, 12.013) ], tumor stage [R^R =5.058 (95% CI: 2.081, 12.293) ], lymph node metastasis [R^R = 3.991 (95% CI: 1.642, 9.699) ], Versican positivity [R^R = 4.263 (95% CI: 1.754, 10.361) ] and WTAP positivity [R^R = 5.038 (95% CI: 2.073, 12.244) ] were independent factors affecting postoperative recurrence or metastasis in gastric cancer patients (P < 0.05). The disease-free survival curves were different between the patients with and without positive expressions of Versican and WTAP (P < 0.05).Conclusions The protein expressions of Versican and WTAP in the cancer tissues of gastric cancer patients are related to the clinicopathological characteristics and prognosis. Patients with positive expressions of Versican and WTAP have a high risk of postoperative recurrence or metastasis.